• Publications
  • Influence
Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives
Platelets play an important role in atherothrombotic disease. The currently available antiplatelet drugs target key steps of platelet activation including thromboxane A2 synthesis, ADP-mediatedExpand
  • 45
  • 2
  • PDF
The Impact of Hemodialysis on the Dispersion of Ventricular Repolarization
Sudden cardiac death is prevalent in chronic hemodialysis (HD) patients while the dialysis process may have arrhythmogenic potential. We sought to examine the effect of HD on conventionalExpand
  • 11
  • 2
The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment
Platelets are involved in thrombus formation and inflammation following vascular injury, while clopidogrel exerts antithrombotic and anti-inflammatory actions. We investigated variousExpand
  • 19
  • 1
The relative value of metabolic syndrome and cardiovascular risk score estimates in premature acute coronary syndromes.
BACKGROUND To compare the relative value of metabolic syndrome (MetS) and cardiovascular risk score estimates in patients with acute coronary syndromes (ACS) aged <45 years. PATIENTS AND METHODSExpand
  • 15
  • 1
Platelet-mediated inflammation in cardiovascular disease. Potential role of platelet-endothelium interactions.
Inflammation of the vascular wall is considered as the principal underlying mechanism in the development of atherosclerosis. Besides their specific functions in haemostasis via thrombus formationExpand
  • 23
Clopidogrel differentially affects platelet‐mediated thrombosis and inflammatory response in patients with acute coronary syndromes
1 Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979; 59: 8–13. 2 Grundy SM, Howard B, Smith S, Eckel R, Redberg R, Bonow RO. Prevention ConferenceExpand
  • 13
Antiplatelet Efficacy of Long-Term Treatment With Clopidogrel Besylate in Patients With a History of Acute Coronary Syndrome
The efficacy of clopidogrel therapy in patients with an acute coronary syndrome (ACS) has been established using the clopidogrel hydrogen sulfate (CHS) formulation. We compared the antiplateletExpand
  • 11
Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate
Objective: The efficacy of clopidogrel therapy in patients with an acute coronary syndrome (ACS) has been established using the clopidogrel hydrogen sulfate (CHS) formulation. In this study weExpand
  • 12
Clopidogrel generic formulations in the era of new antiplatelets: a systematic review.
Clopidogrel is a thienopyridine that selectively and irreversibly inhibits the ADP purinergic receptor P2Y12 and the subsequent ADP-mediated platelet activation. Clopidogrel has been approved forExpand
  • 10
Antiplatelet Treatment in the Secondary Prevention of Coronary and Cerebrovascular Disease
Ischemic heart disease and cerebrovascular disease remain major health problems with associated mortality and quality-of-life consequences. Antiplatelet agents, including thienopyridines and the newExpand
  • 3
...
1
2
...